CN116077512A - Application of Manacastine in relieving multi-organ damage caused by chemotherapeutic drug cisplatin - Google Patents
Application of Manacastine in relieving multi-organ damage caused by chemotherapeutic drug cisplatin Download PDFInfo
- Publication number
- CN116077512A CN116077512A CN202310101885.3A CN202310101885A CN116077512A CN 116077512 A CN116077512 A CN 116077512A CN 202310101885 A CN202310101885 A CN 202310101885A CN 116077512 A CN116077512 A CN 116077512A
- Authority
- CN
- China
- Prior art keywords
- cisplatin
- manacastine
- cells
- mice
- manostatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title claims abstract description 116
- 229960004316 cisplatin Drugs 0.000 title claims abstract description 116
- 230000006378 damage Effects 0.000 title claims abstract description 29
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 14
- 229940044683 chemotherapy drug Drugs 0.000 title abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 claims abstract description 25
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 10
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 10
- 239000011734 sodium Substances 0.000 claims abstract description 10
- 239000004376 Sucralose Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 6
- 235000019408 sucralose Nutrition 0.000 claims abstract description 6
- 231100000331 toxic Toxicity 0.000 claims description 15
- 230000002588 toxic effect Effects 0.000 claims description 15
- 108010010998 polyactin A Proteins 0.000 claims description 13
- 238000002512 chemotherapy Methods 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 206010061481 Renal injury Diseases 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000000857 drug effect Effects 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- -1 kits Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 27
- 210000003734 kidney Anatomy 0.000 abstract description 17
- 210000000813 small intestine Anatomy 0.000 abstract description 14
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 abstract description 9
- 230000002147 killing effect Effects 0.000 abstract description 6
- 210000004881 tumor cell Anatomy 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 4
- 230000000973 chemotherapeutic effect Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 4
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract description 2
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 43
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 25
- 102000012192 Cystatin C Human genes 0.000 description 12
- 108010061642 Cystatin C Proteins 0.000 description 12
- 229940109239 creatinine Drugs 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 238000007619 statistical method Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 201000007270 liver cancer Diseases 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000000556 factor analysis Methods 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 208000037806 kidney injury Diseases 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 210000005084 renal tissue Anatomy 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001744 histochemical effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 206010003497 Asphyxia Diseases 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- 102000018614 Uromodulin Human genes 0.000 description 2
- 108010027007 Uromodulin Proteins 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 231100000857 poor renal function Toxicity 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 231100000268 induced nephrotoxicity Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000010024 tubular injury Effects 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cisplatin is a common chemotherapeutic drug in clinic, which can effectively kill various tumor cells, but its clinical application is greatly limited by its severe side effects. The Mannastine (Manostatin) of the present invention comprises three components: the main component mannose and auxiliary medicines sodium saxoate and sucralose can stay in the digestive tract for a long time and fully contact with intestinal epithelial cells, so that the absorption of cells to the medicine components is increased, and the action time of the medicine is prolonged. After entering normal tissue cells, the Manacastine can inhibit the killing effect of a chemotherapeutic medicament cisplatin on the cells, and experiments show that the Manacastine can effectively inhibit damage of colorectal, small intestine and kidney caused by cisplatin, and meanwhile, the Manacastine does not influence the killing effect of cisplatin on tumor cells, so that a new scheme is provided for the treatment of cancer patients.
Description
Technical Field
The invention relates to the field of medical science and technology, in particular to an application of Manacastine in relieving multi-organ damage caused by chemotherapeutic cisplatin.
Background
Chemotherapy (chemotherapy for short) is the most common cancer treatment means clinically adopted at present, has universality and high efficiency on cancer treatment, cisplatin is a platinum compound and is often used for treating various types of cancers clinically, and the cisplatin can effectively kill tumor cells, but has a systemic action range, and can kill a large number of normal tissue cells when killing the tumor cells, so that severe side effects caused by the cisplatin are also caused. The known side effects of cisplatin at present mainly comprise alopecia, nausea, diarrhea, neuromuscular system injury and the like, wherein most of the side effects are from wrong killing of normal cells of intestinal tracts and kidneys by cisplatin, and no scheme for clearly and effectively solving the side effects generated in the treatment process of cisplatin is available clinically at present.
Manaastatin is a mixed drug of mannose, sodium saxoate and sucralose, wherein mannose has been used for hundreds of years, and is often used for treating urinary tract infection, but the absorption efficiency of the mannose by human body is poor, and by mixing sodium saxoate and sucralose, a mixture is formed, and the mixture can be adhered to digestive tract epithelial cells, so that the residence time of the mixture in the intestinal tract is longer, and meanwhile, the absorption effect of the sodium saxoate on mannose by the intestinal tract epithelial cells can be increased. The components of the Manacastine do not influence the functions of normal cells of a human body, and the application of the Manacastine in tumor treatment is a lack of research.
Disclosure of Invention
The invention aims to provide the application of Manacastine in relieving multi-organ damage caused by cisplatin serving as a chemotherapeutic medicine. The main components of Mannostin (Manostatin) are mannose, sodium saxoate and sucralose, wherein the mannose is a main drug with a pharmacodynamic effect, the sodium saxoate and the sucrose only have an auxiliary effect, and the mannose is a monosaccharide substance.
The invention provides application of Manacastine in medicines, kits, pharmaceutical compositions or health care products for relieving toxic and side effects caused by Cisplatin (Cisplatin), wherein the toxic and side effects are multiple organ injuries.
The organ injury is toxic and side effects of organs such as intestines, kidneys and the like caused by cisplatin.
The kit comprises (i) a reagent comprising Mannastine and (ii) a reagent comprising cisplatin.
The invention provides the use of Manacastine in the manufacture of a medicament for reducing damage to an organ of the digestive tract caused by cisplatin during chemotherapy.
The invention provides application of Manacastine in preparing a medicament for reducing toxic kidney injury caused by cisplatin during chemotherapy.
The medicine is prepared from the following medicament forms: oral liquid, injection, tablet, and capsule.
The beneficial effects of the invention include:
cisplatin is a common clinical chemotherapeutic drug, and can effectively kill various tumor cells, but is greatly limited in clinical application due to severe side effects. The Mannich statin can stay in the digestive tract for a long time and fully contacts with intestinal epithelial cells, so that the absorption of cells to medicine components is increased, and the acting time of the medicine is prolonged. After entering normal tissue cells, the Manacastine can inhibit the killing effect of a chemotherapeutic medicament cisplatin on the cells, and experiments show that the Manacastine can effectively inhibit damage of colorectal, small intestine and kidney caused by cisplatin, and meanwhile, the Manacastine does not influence the killing effect of cisplatin on tumor cells, so that a new scheme is provided for the treatment of cancer patients.
Drawings
FIG. 1 shows that treatment with Cisplatin (Cisplatin) as a chemotherapeutic agent results in colorectal shortening, and that Mannasstatin (Manostatin) according to the present invention can reduce damage to the colorectal of mice caused by Cisplatin (Cisplatin).
FIG. 2 shows the damage of Cisplatin (Cisplatin) to small intestine villi and crypt in mice, including shortening the length of small intestine villi (a) (b) and reducing intact crypt (a) (c), wherein said Mannasstatin (Manostatin) according to the present invention can reduce the damage of Cisplatin (Cisplatin) to small intestine crypt and villi in mice.
FIG. 3 shows a number of lesions of renal morphology and function caused by the chemotherapeutic agent Cisplatin (Cisplatin), including an increase in renal PAS positive staining area (a) (b), a significant increase in Blood Urea Nitrogen (BUN) (C), a significant increase in blood creatinine (d) and a significant increase in blood cystatin C (e), an indication of impaired renal function. The Mannasstatin (Manostatin) can reduce damage of Cisplatin (Cisplatin) to the kidney of a mouse.
FIG. 4 shows that treatment with the chemotherapeutic agent Cisplatin (Cisplatin) or with Mannostin (Manostatin) significantly inhibited tumor growth and decreased tumor number (a) (b) in mice bearing primary liver cancer. The Mannastine (Manostatin) disclosed by the invention does not influence the treatment effect of Cisplatin (Cisplatin) on primary liver cancer tumors of mice.
Detailed Description
In one embodiment, the invention provides a Mannostin (Manostatin) which comprises mannose, sodium saboate and sucralose as main components, wherein the mannose is a main drug for acting the drug effect, and the sodium saboate and the sucrose only have auxiliary effects.
Optionally, the mannatide (Manostatin) alleviates toxic side effects of Cisplatin (Cisplatin) induced organs such as the intestines, kidneys, and the like of mice.
Optionally, the component of Mannastine (Manostatin) does not affect the normal physiological state of each tissue and organ of the body.
Optionally, the mannatine (Manostatin) alleviates the toxic side effects caused by Cisplatin (Cisplatin) without affecting the efficacy of the chemotherapeutic agent.
In one embodiment, the invention provides a kit comprising (i) a reagent comprising Mannastine and (ii) a reagent comprising cisplatin.
In one embodiment, the invention provides a method of reducing intestinal, renal toxic side effects caused by Cisplatin (cispratin), comprising administering to a subject an effective amount of a kit of the invention, which may be administered simultaneously or sequentially comprising (i) an agent comprising Mannastine and (ii) an agent comprising Cisplatin.
In one embodiment, the invention provides a method of reducing toxic side effects caused by Cisplatin (cispratin) without affecting the efficacy of the treatment, comprising administering to a subject an effective amount of a kit of the invention, which may be administered simultaneously or sequentially comprising (i) an agent comprising Manacastin and (ii) an agent comprising Cisplatin.
In one embodiment, the invention provides the use of Manacastine in the manufacture of a medicament for reducing damage to the digestive tract caused by cisplatin at chemotherapy, which medicament reduces the toxic damage to the digestive tract caused by cisplatin at chemotherapy.
In one embodiment, the invention provides the use of Manacastine in the manufacture of a medicament for reducing toxic kidney damage caused by cisplatin at chemotherapy, which medicament can reduce toxic kidney damage caused by cisplatin at chemotherapy.
In one embodiment, the medicaments according to the invention can also be formulated into other pharmaceutically acceptable dosage forms for enteral or parenteral administration, such as oral solutions, injections, tablets, capsules, etc., according to methods known in the art.
The process of carrying out the invention is described in detail below with reference to the accompanying drawings and detailed description for the understanding of those skilled in the art. The following examples are merely illustrative of the invention in question and should not be construed as limiting the scope of the invention in question. If the embodiment does not specify a particular technique or condition, it must be performed according to the methods or conditions described in the literature in the field or according to a product manual. The reagents or tools used are common products on the market unless the manufacturer is identified.
Example 1
Effect of mannatine on chemotherapy-directed cisplatin-induced intestinal and renal damage in mice.
The experimental method is as follows:
1. treatment of mice:
(1) Several C57BL/6 mice (about 20 g) of SPF grade were randomly divided into four groups including control group (Ctrl), mannasstatin group (Manostatin), cisplatin group (Cisplatin), cisplatin/Mannasstatin combined treatment group (Cisplatin+Manostatin), and feeding conditions were 12h light period and 12h dark period.
(2) Mice in the control group (Ctrl) were treated daily with 800 μl of Phosphate Buffer (PBS) for intragastric administration, once daily for 5 days, with the first day being pretreatment, of the mice in the mannatide group (manostatin) and the Cisplatin/mannatide combination treatment group (cispratin+manostatin).
(3) Cisplatin (cispratin) and Cisplatin/Mannostin (cispratin+Manostatin) treatment groups (Cisplatin dissolved in sterile saline) were treated by intraperitoneal injection at a dose of 17mg/kg, and Manostatin pretreatment was injected once.
2. The colorectal length of the mice was measured:
after mice were treated with cisplatin formulation, sacrificed by carbon dioxide asphyxiation, and after dissection, the mice were removed for colorectal observation, length was measured and counted.
3. Histochemical analysis of staining:
the small intestine of the mice was removed to analyze the histochemical staining of H & E:
(1) The inside of the small intestine was rinsed with pre-chilled PBS, the small intestine was cut to a length of about 8 cm, cut longitudinally with scissors, and then the small intestine was rolled into a "Swiss roll" shape with a paperclip.
(2) Small intestine fixed tissues were fixed with 4% paraformaldehyde for 18-24 hours.
(3) The fixed tissue of the small intestine is then dehydrated and paraffin is introduced.
(4) Paraffin sections were performed on the embedded tissues.
(5) The cut tissue was dewaxed and rehydrated, and then stained with hematoxylin eosin.
(6) After natural drying, the films were sealed and then examined microscopically.
The kidneys of mice were removed to analyze the histochemical staining of PAS:
(1) The kidneys of the mice were rinsed with PBS at room temperature.
(2) Kidney tissue was fixed with 4% paraformaldehyde for 24-48 hours.
(3) The fixed tissue is then dehydrated and paraffin is introduced.
(4) Paraffin sections were performed on the embedded tissues.
(5) Dewaxing and rehydrating the cut tissues, and performing PAS staining. PAS staining is also known as snow-fu periodate staining or glycogen staining. Typically used to display glycogen and other polysaccharide materials. Principle of: the periodic acid oxidizes the intracellular polysaccharide glycol groups to glyoxal, which is then combined with the colorless fuchsin of Schiff's fluid to make it red and localized in the cytoplasm. When the kidneys were damaged, uromodulin (Uromodulin) increased drastically and was stained by PAS. PAS staining can therefore reflect the extent of morphological structural damage to the kidneys.
(6) And (5) performing microscopic examination after sealing the sheet.
5. Determination of Blood Urea Nitrogen (BUN), creatinine (Creatinine) and Cystatin C (Cystatin C):
after treatment of mice with cisplatin formulation, blood was taken by extraction of the eyeballs and the blood was stratified at 37 ℃.
The top serum was collected by centrifugation using a high speed centrifuge at 3000rpm for 25 minutes. Serum is sent to hospitals to determine indicators related to kidney function, such as Blood Urea Nitrogen (BUN), creatinine (creatinine) and cystatin C (cystatin C). A significant increase in urea nitrogen (BUN), creatinine, and cystatin C levels in the blood suggests impaired renal function.
Manacastine reduced cisplatin results of colorectal injury test in mice are shown in FIG. 1.
Figure 1 Manacastine can alleviate cisplatin-induced colorectal shortening in mice. There was no significant change in colorectal length in the Manlastin group (Manostatin) compared to the control group (Ctrl), the colorectal length in the Cisplatin group was significantly shortened compared to the control group (Ctrl), and the colorectal length in the Cisplatin/Manlastin co-treated group (Cisplatin+Manostatin) was significantly normalized compared to the Cisplatin (Cisplatin) group. The Manacastine treatment disclosed by the invention does not influence the colorectal length of experimental mice, but can reduce the damage to the colorectal of the mice caused by chemotherapy-guided administration of cisplatin.
Statistical analysis was performed on the obtained data using Graphpad prism 9 statistical software, and experimental data were expressed as mean ± standard error. The difference between the control group and the experimental group is analyzed by adopting a two-factor analysis of variance and Fisher test, ns represents p >0.05, and the difference has no statistical significance. * P <0.05, the difference is significant; * Represents p <0.01, the difference is highly significant; indicating p <0.001, the difference was very significant; statistical analysis showed that Manacastine treatment did not affect the colorectal length of mice (p > 0.05), but could alleviate colorectal damage in mice caused by chemotherapy-directed cisplatin administration (p < 0.001).
Manacastine reduced cisplatin results of mice intestinal function and structural injury assays are shown in FIG. 2.
Figure 2 Manacastine can alleviate cisplatin-induced small intestine villus shortening and crypt loss. The Manniche length and number of the Mannastine group were unchanged compared to the control group (Ctrl), the small intestine villus number and small intestine crypt number of the Cisplatin group (Cisplatin) were reduced compared to the control group (Ctrl), and the treatment group receiving Cisplatin/Mannastine (Cisplatin+Manostatin) was significantly restored to normal compared to the Cisplatin group mice (Cisplatin).
Statistical analysis was performed on the obtained data using Graphpad prism 9 statistical software, and experimental data were expressed as mean ± standard error. The difference between the control group and the experimental group is analyzed by adopting a two-factor analysis of variance and Fisher test, ns represents p >0.05, and the difference has no statistical significance. * P <0.05, the difference is significant; * Represents p <0.01, the difference is highly significant; indicating p <0.001, the difference was very significant; statistical analysis showed that mannatide treatment did not affect the mouse intestinal villus and crypt (p > 0.05), but could alleviate the damage to the mouse intestinal villus and crypt caused by chemotherapy-directed cisplatin administration (p < 0.001).
Results of the release of cisplatin-induced nephrotoxicity in mice by Manacastine are shown in FIG. 3.
Fig. 3a, b. Manacastine can reduce cisplatin-induced kidney injury in mice. The kidney tissue of the mannatide group (Ctrl) was unchanged compared to the control group (Ctrl), whereas the Cisplatin group (cispratin) showed a significant increase in the positive area of kidney-stained PAS compared to the control group (Ctrl) mice, and the evaluation of tubular injury also showed significant kidney injury, and the combination treatment of Cisplatin/mannatide group (cispratin+manostatin) significantly restored the normal state compared to the kidney tissue of the Cisplatin (cispratin) group, and the evaluation of kidney injury also significantly indicated an improvement in deterioration. The Mannich statin treatment disclosed by the invention does not influence the normal physiological structure and function of the kidney of the mouse, but can relieve the damage of the kidney tissue of the mouse caused by chemotherapy-guided administration of cisplatin.
Statistical analysis was performed on the obtained data using Graphpad prism 9 statistical software, and experimental data were expressed as mean ± standard error. The difference between the control group and the experimental group is analyzed by adopting a two-factor analysis of variance and Fisher test, ns represents p >0.05, and the difference has no statistical significance. * P <0.05, the difference is significant; * Represents p <0.01, the difference is highly significant; indicating p <0.001, the difference was very significant; statistical analysis showed that mannatine treatment did not affect the kidney of mice (p > 0.05), but could alleviate tissue damage in the kidney of mice caused by the chemotherapeutic drug cisplatin (p < 0.001).
Fig. 3c, d, e. Mannatide can reduce cisplatin-induced impairment of renal function. The levels of Blood Urea Nitrogen (BUN), creatinine (Creatinine) and Cystatin C (Cystatin C) were not significantly changed in the mannastine group (Manostatin) compared to the control group (Ctrl) and the levels of Blood Urea Nitrogen (BUN), creatinine (Creatinine) and Cystatin C (Cystatin C) were significantly increased in the Cisplatin/mannastine co-treated group (cispratin + Manostatin) compared to the Cisplatin group (cispratin) and the levels of Blood Urea Nitrogen (BUN), creatinine (Creatinine) and Cystatin C (Cystatin C) were significantly reduced in the Cisplatin group (cispratin) mice. The Mannich treatment disclosed by the invention does not affect the kidney of the mouse, but can reduce the damage of the kidney function of the mouse caused by cisplatin as a chemotherapeutic drug.
Statistical analysis was performed on the obtained data using Graphpad prism 9 statistical software, and experimental data were expressed as mean ± standard error. The difference between the control group and the experimental group is analyzed by adopting a two-factor analysis of variance and Fisher test, ns represents p >0.05, and the difference has no statistical significance. * P <0.05, the difference is significant; * Represents p <0.01, the difference is highly significant; indicating p <0.001, the difference was very significant; statistical analysis showed that mannatide treatment did not affect kidney function in mice (p > 0.05), but reduced kidney function impairment in mice caused by the chemotherapeutic drug cisplatin (p < 0.001).
Example 2
Influence of Manacastine on the effect of chemotherapy-guided cisplatin on inhibiting the occurrence and development of primary liver cancer.
The experimental method is as follows:
1. treatment of mice:
(1) Establishing a primary liver cancer model of a mouse: male mice were intraperitoneally administered diethylnitrosamine (DEN in PBS) at a dose of 25mg/kg 14 days postnatally, and carbon tetrachloride (CCl 4 in corn oil) at a dose of 0.5mL/kg weekly for about 3-4 months after one week.
(2) Mice induced by successful liver cancer are randomly divided into a control group, a Mannostin group, a cisplatin group and a cisplatin/Mannostin combined treatment group, and feeding conditions are a 12h illumination period and a 12h dark period.
(3) Mice in the control group (Ctrl) were gavaged daily with 800 μl of Phosphate Buffer (PBS), manostatin group (manostatin) and Cisplatin/manostatin combination treatment group (cisplatin+manostatin) mice were gavaged with 800 μl of manostatin (manostatin, in solution form) using gavage, once daily for a pretreatment time of one day, and post-treatment for 4 weeks.
(4) Cisplatin (cispratin, dissolved in sterile saline) and Cisplatin/Mannostin co-treatment group (cispratin+Manostatin) mice were subjected to Cisplatin (cispratin, dissolved in sterile saline) treatment by intraperitoneal injection at a dose of 17mg/kg once a week for 4 weeks.
2. Primary liver cancer tumor number:
after treatment of mice with cisplatin formulation, mice were sacrificed by carbon dioxide asphyxiation, and after dissection, the mice were removed from the liver and tumor numbers were recorded.
Manacastine does not affect the inhibition of primary liver cancer by cisplatin, a chemotherapeutic drug, as shown in FIG. 4.
Fig. 4. The volume and number of liver tumors in the Cisplatin group (cispratin) compared to the control group (Ctrl) were significantly reduced/decreased, whereas the volume and number of liver tumors in the Cisplatin/mannastine co-treated group (cispratin + manostatin) compared to the Cisplatin group (cispratin) mice were unchanged. The invention shows that the Manacastine does not influence the inhibition effect of the chemotherapeutic drug cisplatin on the primary liver cancer.
Statistical analysis was performed on the obtained data using Graphpad prism 9 statistical software, and experimental data were expressed as mean ± standard error. The difference between the control group and the experimental group is analyzed by adopting a two-factor analysis of variance and Fisher test, ns represents p >0.05, and the difference has no statistical significance. * P <0.05, the difference is significant; * Represents p <0.01, the difference is highly significant; indicating p <0.001, the difference was very significant; statistical analysis shows that the Manacastine does not influence the inhibition effect (p > 0.05) of the chemotherapeutic drug cisplatin on the primary liver cancer.
Claims (6)
1. The application of the mannatide in medicines, kits, pharmaceutical compositions or health care products for relieving toxic and side effects caused by Cisplatin (Cisplatin), wherein the toxic and side effects are multi-organ injuries, the main components of the mannatide (Manostin) are mannose, sodium sahexanoate and sucralose, the mannose is the main medicine for acting in a drug effect, and the sodium sahexanoate and sucrose only act in an auxiliary effect.
2. The use according to claim 1, wherein the organ injury is a toxic side effect of cisplatin on the intestinal, renal and other organs.
3. Use according to claim 1, characterized in that the medicament is made in the form of: oral liquid, injection, tablet, and capsule.
4. The use according to claim 1, characterized in that the kit comprises (i) an agent comprising mannatide and (ii) an agent comprising cisplatin.
5. Use of mannatide in the manufacture of a medicament for reducing damage to an organ of the digestive tract caused by cisplatin during chemotherapy.
6. Use of mannatide in the manufacture of a medicament for reducing cisplatin-induced toxic renal injury upon chemotherapy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310101885.3A CN116077512A (en) | 2023-02-08 | 2023-02-08 | Application of Manacastine in relieving multi-organ damage caused by chemotherapeutic drug cisplatin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310101885.3A CN116077512A (en) | 2023-02-08 | 2023-02-08 | Application of Manacastine in relieving multi-organ damage caused by chemotherapeutic drug cisplatin |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116077512A true CN116077512A (en) | 2023-05-09 |
Family
ID=86202352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310101885.3A Withdrawn CN116077512A (en) | 2023-02-08 | 2023-02-08 | Application of Manacastine in relieving multi-organ damage caused by chemotherapeutic drug cisplatin |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116077512A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023217179A1 (en) * | 2022-05-11 | 2023-11-16 | 厦门大学 | Use of mannose in inhibiting pyroptosis or relieving toxic and side effects of chemotherapy drug |
-
2023
- 2023-02-08 CN CN202310101885.3A patent/CN116077512A/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023217179A1 (en) * | 2022-05-11 | 2023-11-16 | 厦门大学 | Use of mannose in inhibiting pyroptosis or relieving toxic and side effects of chemotherapy drug |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2455002C2 (en) | Composition containing oridonin and applicable for treating resistant malignant tumours | |
BRPI0710541A2 (en) | treatment of inflammatory and ulcerative bowel diseases with opioid antagonists | |
CN113274342B (en) | Colchicine external composition | |
CN107213149B (en) | Application of artemisinin derivatives in preparation of drugs for treating or assisting in treating autoimmune thyroid diseases | |
JP2011529078A (en) | Methods and compositions for treating and preventing autoimmune diseases | |
JPS61151123A (en) | Immuno-regulator | |
CN116077512A (en) | Application of Manacastine in relieving multi-organ damage caused by chemotherapeutic drug cisplatin | |
JPH0930987A (en) | Preparation for treating and preventing intractable ulcer, gastritis and dermatitis | |
Ueoka et al. | Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study | |
US20200170990A1 (en) | Method for treating schnitzler's syndrome | |
CN100382799C (en) | Power for intravenous injection with liver-protecting action, and its preparation and quality control method | |
Weiss, G. & Serfontein | The efficacy of a bismuth-protein-complex compound in the treatment of gastric and duodenal ulcers | |
AU2017287461B2 (en) | Application of methyl 4-[9-(6-aminopuryl)]-2(S)-hydroxybutyrate in preparation of medicament for treating psoriasis and vitiligo | |
KR0156623B1 (en) | Remedy composition for epithelial cell | |
RU2739746C9 (en) | Pharmaceutical agent for arthritic diseases treatment | |
CN112386600B (en) | Application of Hupeimine in preparation of medicine for preventing acute kidney injury | |
CN116036102A (en) | Use of Manacastine to reduce intestinal damage caused by XELOX combination treatment regimen | |
CN112826820B (en) | NLRP3 inhibitor and application thereof | |
CN116270674A (en) | Application of Manacastine in relieving toxic and side effects of oxaliplatin | |
KR20000014188A (en) | Kidney protecting agent composition containing processed ginseng extract | |
CN114306350B (en) | Application of cholesterol sulfate in preparation of medicine for preventing sepsis | |
WO2024012531A1 (en) | Use of pyridone derivative | |
CN116660252A (en) | Test method of chemotherapeutic synergistic medicine Mannastine medicament | |
CN114712379A (en) | Application of astragaloside IV in preparation of medicine for preventing and treating peritoneal dialysis intestinal complications | |
RU2305552C2 (en) | Agent with hematopoietic action |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230509 |